ASH 2023 | Sorafenib as maintenance therapy for patients with transplant-ineligible or post-alloSCT AML
Musa Yilmaz, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the optimization of maintenance therapy to reduce the risk of relapse post-transplant or in patients who are not eligible for transplant with FLT3-mutated acute myeloid leukemia (AML). Dr Yilmaz mentions a clinical trial that shows an overall survival (OS) benefit of sorafenib post-allogeneic stem cell transplantation (alloSCT) in patients with AML, indicating this as an effective maintenance therapy strategy. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Pfizer, Daiichi-Sankyo
